Search for Clinical Trial Results

Sponsored By

Post-transplant Lymphoproliferative Disease - 12 Studies Found

Status Study
Completed Study Name: Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
Condition:
  • Post-transplant Lymphoproliferative Disease (PTLD)
  • Non Burkitt<
    Date: 2010-03-11
    Interventions: Drug: fludarabine, cyclophosphamide, doxorubicin, rituximab Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); C
Recruiting Study Name: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
Condition: Posttransplant Lymphoproliferative Disorder
Date: 2014-01-20
Interventions:
  • Drug: Rituximab sc All patient
Active, not recruiting Study Name: Bortezomib Plus Rituximab for EBV+ PTLD
Condition:
  • Post-transplant Lymphoproliferative Disease
  • Solid Organ Transpl
    Date: 2010-01-26
    Interventions:
    • Drug: bortezomib Given intrave
Not yet recruiting Study Name: Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
Condition:
  • Post-transplant Lymphoproliferative Disease
  • Transplant-Related
    Date: 2017-04-24
    Interventions:
    • Biological: Autologous EBV-CTL transduced with vector SFG-CNA12

Recruiting Study Name: Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Condition:
  • Epstein Barr Virus Associated Non Hodgkin's Lymphoma
  • Epstein Barr Virus Associated Hodgkin's
    Date: 2013-10-14
    Interventions:
    • Drug: Doxorubicin Doxorubicin

Terminated Study Name: Relationship Between EBV and PTLD
Condition: Pediatric Heart Transplant
Date: 2005-09-20
Terminated Study Name: Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation
Condition: Lymphoproliferative Disorder
Date: 2002-04-09
Interventions: Biological: therapeutic allogeneic lymphocytes
Completed Study Name: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
Condition:
  • Post-transplant Lymphoproliferative Disorder
  • Recurrent Adult Burkitt Lymphoma
  • Date: 2003-07-08
    Interventions:
    • Biological: rituximab Given IV
Terminated Study Name: Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Condition:
  • Leukemia
  • Lymphoma
  • Lymphoproliferative Disorder

Date: 2004-07-08
Interventions:
  • Biological: beta-glucan Given

Recruiting Study Name: Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive Cluster of Differentiation(CD) 20-Positive Post-Transplant Lymphoproliferative Disorder
Condition:
  • Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder
  • Monomorphic Post-Tra
    Date: 2016-09-06
    Interventions:
    • Biological: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes

Next >>>